Excision’s HIV gene editing clinical trial; Nykode’s $45M placement; Ideaya’s post-ESMO offering

25 Oct 2023

Gene TherapyClinical StudyClinical Result

Plus, news from Skye Bioscience, Mediar Therapeutics and Servier. A first look at Excision’s HIV gene editing clinical trial: The company said Wednesday that three patients have been dosed in the Phase I/II study so far, with mild grade 1 side effects related to the therapy, known as EBT-101. Two of the three participants experienced brief elevation in liver enzymes, a concern related to therapies like EBT-101 that use viral vectors for delivery. However, there were no infusion-related reactions or complement-mediated toxicity, a type of immune response. The results were presented at the European Society of Gene & Cell Therapy’s annual meeting.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Excision Medical, Inc.

Nykode Therapeutics ASA

IDEAYA Biosciences, Inc.

[+3]

Indications

Targets

Drugs

EBT-101

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.